Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Option Care Health (OPCH) Interest & Investment Income (2018 - 2025)

Option Care Health (OPCH) has disclosed Interest & Investment Income for 8 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 870.39% year-over-year to $19.8 million, compared with a TTM value of $7.4 million through Dec 2025, up 124.53%, and an annual FY2025 reading of $7.4 million, up 24.23% over the prior year.
  • Interest & Investment Income was $19.8 million for Q4 2025 at Option Care Health, up from -$15.5 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $73.1 million in Q2 2023 and bottomed at -$70.3 million in Q4 2023.
  • Average Interest & Investment Income over 5 years is -$4.3 million, with a median of -$5.0 million recorded in 2022.
  • The sharpest move saw Interest & Investment Income crashed 6733.58% in 2023, then soared 870.39% in 2025.
  • Year by year, Interest & Investment Income stood at -$13.8 million in 2021, then skyrocketed by 107.68% to $1.1 million in 2022, then plummeted by 6733.58% to -$70.3 million in 2023, then skyrocketed by 102.91% to $2.0 million in 2024, then skyrocketed by 870.39% to $19.8 million in 2025.
  • Business Quant data shows Interest & Investment Income for OPCH at $19.8 million in Q4 2025, -$15.5 million in Q3 2025, and $1.4 million in Q2 2025.